https://pubmed.ncbi.nlm.nih.gov/22736724/
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors
Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. Pasireotide is a somatostatin analog with binding affinity to a broader range of...
phase i study
https://adisinsight.springer.com/trials/700374295?error=cookies_not_supported&code=da73d30c-e731-4283-bf0a-1d9d131884e7
Pasireotide as Maintenance Treatment With Monthly Deep Intramuscular Injection in...
PAMSARC is a non-commercial interventional Phase 2 clinical trial of academic research institutions, with its primary goal being to improve medical treatment
intramuscular injectionmaintenancetreatmentmonthlydeep
https://pubmed.ncbi.nlm.nih.gov/32385851/
Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results...
https://adisinsight.springer.com/trials/700391300?error=cookies_not_supported&code=6d4e998c-9e34-4b73-a9f6-7d796a9281a2
Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous...
https://op.europa.eu/en/web/public-procurement/procurement-details/-/procurement/b18c9da5-909e-45da-8c70-4c7867237752
Medicinal products containing octreotide, lanreotide and pasireotide - EU tenders - Publications...
medicinal productseu tenderscontainingoctreotidelanreotide